

PE Streptavidin

Catalog# / Size	405203 / 100 µg 405204 / 500 µg
Regulatory Status	RUO
Other Names	Streptavidin-Phycoerythrin, SAV-PE
Description	Streptavidin binds to biotin with high affinity. Streptavidin-Phycoerythrin (PE) is useful for detecting biotinylated antibodies. The excitation of PE by 488 nm laser light induces a light emission maximum of 575 nm.

Product Details

Verified Reactivity	Human, Mouse, Rat, All Species
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	Streptavidin is conjugated with PE under optimal conditions.
Concentration	0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling	The streptavidin-PE solution should be stored undiluted between 2°C and 8°C, and protected from exposure to light. Do not freeze.
Application	FC - Quality tested ICFC - Verified
Recommended Usage	This streptavidin product is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the PE conjugation. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Streptavidin-Phycoerythrin (PE) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-PE is 360 kD and Streptavidin alone is 52 kD.
Application References	<ol style="list-style-type: none"> Chappaz S, <i>et al.</i> 2007. <i>Blood</i> doi:10.1182/blood-2007-02-074245. Nishimoto KP, <i>et al.</i> 2008. <i>J. Immunol.</i> 181:4010. PubMed Niki T, <i>et al.</i> 2009. <i>J. Biol. Chem.</i> 284:32344. PubMed Shibui A, <i>et al.</i> 2011. <i>Exp Parasitol.</i> 129:318. PubMed Scatizzi JC, <i>et al.</i> 2012. <i>J. Immunol.</i> 188:3307. PubMed Yamakawa N, <i>et al.</i> 2012. <i>Int Immunol.</i> 25:45. PubMed Shibata T, <i>et al.</i> 2012. <i>Int Immunol.</i> 24:613. PubMed Baccala R, <i>et al.</i> 2012. <i>J. Immunol.</i> 189:5976. PubMed Grevers LC, <i>et al.</i> 2013. <i>Ann Rheum Dis.</i> 72:278. PubMed Woo SJ, <i>et al.</i> 2013. <i>J Leukoc Biol.</i> 93:363. PubMed Ashbaugh JJ, <i>et al.</i> 2013. <i>J. Immunol.</i> 190:4525. PubMed Reading JL, 2013. <i>J. immunol.</i> 190:4542. PubMed Kanno A, <i>et al.</i> 2013. <i>Int Immunol.</i> 25:413. PubMed Gunaydin G, <i>et al.</i> 2014. <i>Vaccine.</i> 32:470. PubMed Lyngaa R, <i>et al.</i> 2014. <i>Clin Cancer Res.</i> 20:1768. PubMed Datta S, <i>et al.</i> 2014. <i>J Leukoc Biol.</i> 95:853. PubMed He X, <i>et al.</i> 2014. <i>J Immunol.</i> 193:1314. PubMed Wang W, <i>et al.</i> 2014. <i>PNAS.</i> 111:14466. PubMed Murakami Y, <i>et al.</i> 2014. <i>J Immunol.</i> 193:5208. PubMed Lucas A, <i>et al.</i> 2015. <i>PLoS One.</i> 10:117160. PubMed Kim Yu, <i>et al.</i> 2015. <i>PLoS One.</i> 10:120294. PubMed Hua X, <i>et al.</i> 2015. <i>PLoS One.</i> 10:128039. PubMed
(PubMed link indicates BioLegend citation)	

Product Citations

- Martinez-Blanco Á, *et al.* 2021. *Front Immunol.* 12:713697. [PubMed](#)

2. Zhang Y, *et al.* 2017. Journal of Immunological Methods. 10.1016/j.taap.2017.05.020. [PubMed](#)
3. Wang H, *et al.* 2020. Mol Oncol. 14:991. [PubMed](#)
4. Eger C, *et al.* 2016. PLoS One. 11: 0150479. [PubMed](#)
5. Yang J, *et al.* 2016. Sci Rep. 6:38238. [PubMed](#)
6. Chen T, *et al.* 2016. J Exp Med. 13(13):3025-3039. [PubMed](#)
7. Lv X, *et al.* 2022. Acta Pharm Sin B. 12:735. [PubMed](#)
8. Muliaditan T, *et al.* 2021. Cell Rep Med. 2:100457. [PubMed](#)
9. Tian L, *et al.* 2021. Int J Mol Sci. 22: . [PubMed](#)
10. Trendel N, *et al.* 2021. Sci Signal. 14:eaay9363. [PubMed](#)
11. Gatineau J, *et al.* 2022. Front Immunol. 13:982839. [PubMed](#)
12. Delás MJ, *et al.* 2019. Cell Rep. 27:719. [PubMed](#)
13. Viborg N, *et al.* 2019. Oncoimmunology. 8:e1663107. [PubMed](#)
14. Yamakawa N, *et al.* 2012. Int Immunol. 25:45. [PubMed](#)
15. Grevers L, *et al.* 2013. Ann Rheum Dis. 72:278. [PubMed](#)
16. Datta S, *et al.* 2014. J Leukoc Biol. 95:853. [PubMed](#)
17. Larsen SB, *et al.* 2021. Cell Stem Cell. .: [PubMed](#)
18. Hernandez-Franco JF, *et al.* 2022. Front Immunol. 13:990900. [PubMed](#)
19. Liang Q, *et al.* 2022. iScience. 25:104043. [PubMed](#)
20. Xiao C, *et al.* 2022. iScience. 25:103934. [PubMed](#)
21. Imbrechts M, *et al.* 2022. iScience. 25:104705. [PubMed](#)
22. Biswas S, *et al.* 2021. Nature. 591:464. [PubMed](#)
23. Wellner A, *et al.* 2021. Nat Chem Biol. 17:1057. [PubMed](#)
24. Ruiz-Camp J, *et al.* 2019. EMBO Mol Med. 11:3. [PubMed](#)
25. Nie X, *et al.* 2017. Cellular & Molecular Immunology. 10.1038/cmi.2017.17. [PubMed](#)
26. Gniffke EP, *et al.* 2020. medRxiv. . [PubMed](#)
27. Hu Y, *et al.* 2022. Nat Commun. 13:5313. [PubMed](#)
28. Hayatsu N *et al.* 2017. Immunity. 47(2):268-283 . [PubMed](#)
29. Fukushima T, *et al.* 2019. Cell Rep. 29:4144. [PubMed](#)
30. Ashbaugh J, *et al.* 2013. J Immunol. 190:4525. [PubMed](#)
31. Kim Y, *et al.* 2015. PLoS One. 10:120294. [PubMed](#)
32. Yamamoto K, *et al.* 2021. Cell Reports. 36(8):109576. [PubMed](#)
33. Cao Y, *et al.* 2022. Nature. .: [PubMed](#)
34. He X, *et al.* 2021. Emerg Microbes Infect. 10:1555. [PubMed](#)
35. Nishimoto K, *et al.* 2008. J Immunol. 181:4010. [PubMed](#)
36. Im S, *et al.* 2016. Nature. 537:417-421. [PubMed](#)
37. Schanda N, *et al.* 2021. Cells. 10: . [PubMed](#)
38. Tsukamoto H, *et al.* 2013. Biochem Biophys Res Commun. 440:31. [PubMed](#)
39. Phiwpan K, *et al.* 2015. PLoS One. 10:128198. [PubMed](#)
40. Weiß S, *et al.* 2020. J Infect Dis. 222:1629. [PubMed](#)
41. Pfenninger P, *et al.* 2022. Front Immunol. 13:777113. [PubMed](#)
42. Kristensen NP, *et al.* 2022. J Clin Invest. 132: . [PubMed](#)
43. Qiu C, *et al.* 2022. Front Immunol. 12:764949. [PubMed](#)
44. Cao Y, *et al.* 2022. Nature. 602:657. [PubMed](#)
45. Rogers BM, *et al.* 2021. J Exp Med. 218: . [PubMed](#)
46. Niki T, *et al.* 2009. J Biol Chem. 284:32344. [PubMed](#)
47. Ping Y, *et al.* 2020. Front Cell Dev Biol. 0.890972222. [PubMed](#)
48. Lv Z, *et al.* 2020. Oncoimmunology. 9:1747688. [PubMed](#)
49. Köchl R, *et al.* 2020. Elife. 9:00. [PubMed](#)
50. Lucas A, *et al.* 2015. PLoS One. 10:117160. [PubMed](#)
51. Morimoto A, *et al.* 2021. Nat Commun. 12:2136. [PubMed](#)
52. Mei H, *et al.* 2021. J Hematol Oncol. 14:161. [PubMed](#)
53. Repáraz D, *et al.* 2022. J Immunother Cancer. 10: . [PubMed](#)
54. Dietmar Herndler-Brandstetter *et al.* 2018. Immunity. 48(4):716-729 . [PubMed](#)
55. Kim C, *et al.* 2019. Cell Rep. 29:2202. [PubMed](#)
56. Hansen UK, *et al.* 2020. Front Immunol. 11:373. [PubMed](#)
57. Reading J, *et al.* 2013. J Immunol. 190:4542. [PubMed](#)
58. Weiß S, *et al.* 2020. medRxiv. . [PubMed](#)
59. Hebban N, *et al.* 2022. Nat Commun. 13:587. [PubMed](#)
60. Tschisnarov R, *et al.* 2021. JCI Insight. 6: . [PubMed](#)
61. Richardson LS, *et al.* 2020. Lab Chip. 3.948611111. [PubMed](#)
62. Van Gool F, *et al.* 2019. Immunity. 50:362. [PubMed](#)
63. Kacherovsky N, *et al.* 2019. Nat Biomed Eng. 0.66875. [PubMed](#)
64. McWilliam H, *et al.* 2016. Nat Immunol. 17: 531-537. [PubMed](#)
65. Zhang S, *et al.* 2016. Sci Transl Med. 8: 341ra77. [PubMed](#)
66. Parente-Pereira AC, *et al.* 2022. STAR Protoc. 3:101319. [PubMed](#)
67. Baltierra-Urbe SL, *et al.* 2021. Eur J Immunol. 51:2641. [PubMed](#)
68. Schoutrop E, *et al.* 2022. Oncoimmunology. 11:2093426. [PubMed](#)
69. Jiang Y, *et al.* 2021. Cell Death Differ. 28:3009. [PubMed](#)
70. Delacher M, *et al.* 2020. Immunity. 52:295. [PubMed](#)
71. Tsukamoto H, *et al.* 2017. FEBS Lett. 10.1002/1873-3468.12768. [PubMed](#)
72. Mainini F, *et al.* 2015. PLoS One. 10: 0145403. [PubMed](#)
73. Woo S, *et al.* 2013. J Leukoc Biol. 93:363. [PubMed](#)
74. Baccala R, *et al.* 2012. J Immunol. 189:5976. [PubMed](#)
75. Guo C, *et al.* 2021. Cell Rep Med. 2:100448. [PubMed](#)
76. Chen YL, *et al.* 2021. J Biol Chem. :101420. [PubMed](#)
77. Zhong MC, *et al.* 2021. J Exp Med. 218: . [PubMed](#)
78. Mudd PA, *et al.* 2022. Cell. 185:603. [PubMed](#)
79. Tian B, *et al.* 2017. Front Immunol. 10.3389/fimmu.2017.00956. [PubMed](#)
80. Schoofs T *et al.* 2019. Immunity. 50(6):1513-1529 . [PubMed](#)
81. Carestia A, *et al.* 2019. Cell Rep. 28:896. [PubMed](#)

82. Scatizzi J, *et al.* 2012. J Immunol. 188:3307. [PubMed](#)
83. Günaydin G, *et al.* 2014. Vaccine. 32:470. [PubMed](#)
84. Matt P, *et al.* 2015. PLoS One. 10: 0137474. [PubMed](#)
85. Davis Z, *et al.* 2016. PLoS Pathog. 12: 1005421. [PubMed](#)
86. Roewe J, *et al.* 2020. Nat Commun. 3.260416667. [PubMed](#)
87. Matsuda T, *et al.* 2022. iScience. 25:105324. [PubMed](#)
88. Kim SP, *et al.* 2022. Cancer Immunol Res. :OF1. [PubMed](#)
89. Cheloha RW, *et al.* 2021. RSC chem biol. 2:1692. [PubMed](#)
90. Okamoto Y, *et al.* 2021. J Cell Sci. 134:. [PubMed](#)
91. Leung EYL, *et al.* 2020. Mol Ther Oncolytics. 16:289. [PubMed](#)
92. Nowak W, *et al.* 2020. EBioMedicine. 50:290-305.. [PubMed](#)
93. Gniffke EP, *et al.* 2020. J Infect Dis. 222:1965. [PubMed](#)
94. Morikawa M, *et al.* 2016. PLoS One. 11:e0163607. [PubMed](#)
95. Hoffmann J, *et al.* 2021. Nat Commun. 12:3964. [PubMed](#)
96. Andersen TK, *et al.* 2019. NPJ Vaccines. 4:9. [PubMed](#)
97. Lu X, *et al.* 2019. Cell Rep. 28:472. [PubMed](#)
98. Wang W, *et al.* 2014. Proc Natl Acad Sci U S A. 111:14466. [PubMed](#)
99. Miyauchi K, *et al.* 2016. Nat Immunol. 17:1447-1458. [PubMed](#)
100. Leary N, *et al.* 2022. J Extracell Vesicles. 11:e12197. [PubMed](#)
101. Dan JM, *et al.* 2021. Science. :371. [PubMed](#)
102. He X, *et al.* 2014. J Immunol. 193:1314. [PubMed](#)
103. Kanno A, *et al.* 2013. Int Immunol. 25:413. [PubMed](#)
104. Walker MR, *et al.* 2022. Sci Adv. 8:eabj9513. [PubMed](#)
105. Yang Zhou J, *et al.* 2022. Front Immunol. 13:898473. [PubMed](#)
106. Deng J, *et al.* 2021. J Leukoc Biol. 110:1171. [PubMed](#)
107. Murakami Y, *et al.* 2014. J Immunol. 193:5208. [PubMed](#)
108. Mchedlidze T, *et al.* 2016. Mucosal Immunol. 10.1038/mi.2016.20. [PubMed](#)
109. Wang EY, *et al.* 2022. Cell Rep Methods. 2:. [PubMed](#)
110. Kurashima Y, *et al.* 2021. Nat Commun. 12:1067. [PubMed](#)
111. Wells DK, *et al.* 2020. Cell. 183:818. [PubMed](#)
112. Chappaz S, *et al.* 2010. J Immunol. 185:3514. [PubMed](#)
113. Altman JB, *et al.* 2018. Health Sci Rep. 1:e74. [PubMed](#)
114. Hirunwidchayarat W, *et al.* 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.07.012. [PubMed](#)
115. Schürch CM, *et al.* 2020. Cell. 182:1341. [PubMed](#)
116. DanDan Huang, Lang Bao 2016. J Microbiol Immunol Infect. 49:859-865. [PubMed](#)
117. Xiao C, *et al.* 2021. STAR Protoc. 2:100789. [PubMed](#)
118. Rodrigues KA, *et al.* 2021. Sci Adv. 7:eabj6538. [PubMed](#)
119. Szeto C, *et al.* 2022. Nat Commun. 13:4951. [PubMed](#)
120. Zheng Q, *et al.* 2017. Mol Oncol. 10.1002/1878-0261.12056. [PubMed](#)
121. Pedersen NW, *et al.* 2019. Nat Commun. 10:837. [PubMed](#)
122. Yang C, *et al.* 2019. Nat Commun. 10:3931. [PubMed](#)
123. Lyngaa R, *et al.* 2014. Clin Cancer Res. 20:1768. [PubMed](#)
124. Tripathi S, *et al.* 2016. Proc Natl Acad Sci U S A. 113: 1555 - 1564. [PubMed](#)
125. Ando Y, Oku T, Tsuji T 2016. PLoS One. 11: 0162208. [PubMed](#)
126. Holm JS, *et al.* 2022. Nat Commun. 13:1935. [PubMed](#)
127. Wirasinha RC, *et al.* 2021. J Exp Med. 218: . [PubMed](#)
128. Lautz JD, *et al.* 2019. Sci Rep. 9:10890. [PubMed](#)
129. Kenney M, *et al.* 2017. Journal of Immunological Methods. 10.1016/j.jim.2017.07.001. [PubMed](#)
130. Du Z, *et al.* 2020. J Allergy Clin Immunol. . [PubMed](#)
131. Yoshikawa S, *et al.* 2016. Sci Rep. 6:18738. [PubMed](#)
132. Shibui A, *et al.* 2011. Exp Parasitol. 129:318. [PubMed](#)

Antigen Details


Gene ID NA

Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Product Data

C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587